In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best of the Blog: IN VIVO February 2009

Executive Summary

A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.
Advertisement

Related Content

Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Endo Branches Out With $370M Indevus Acquisition
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
Venture Prepares for Structured Acquisitions
Merck Commercial Model: Expand Customer Base, Tighten Marketing Spend
Pharma's Strategic Divide: Focus or Diversify
Pharma's Strategic Divide: Focus or Diversify

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel